Q. Children, even young ones, are always so busy these days. But have we gone too far?
Discussing phase 3 data of Panzyga for PANS, with Michael Daines, MD
In this video interview, Michael Daines, MD, explains phase 3 data for Panzyga (Octapharma) for pediatric acute- onset neuropsychiatric syndrome (PANS).
Food Insecurity and the Dangers of Infant Formula Dilution
Addictive screen use tied to youth mental health risks
Addictive use of screens—not total time—was linked to higher risks of suicidal behavior and mental health issues in early adolescents.
Demystifying Infant Formula
FDA approves twice-yearly lenacapavir as PrEP for HIV in adolescents, adults
Lenacapavir is the first twice-yearly option available in the US for those who need or want PrEP, according to Gilead Sciences.
Olivia is helping patients and families understand the experience of blood cancer
